2739
CONCLUSIONS: Patients receiving intravitreal injections of bevacizumab should be evaluated for potential systemic risk factors such as carotid insufficiency, coagulopathy and poorly controlled diabetes mellitus.
 carotid insufficiency, coagulopathy and poorly controlled diabetes mellitus: Effect; intravitreal injections of bevacizumab: Treatment; bevacizumab: Treatment.Drug; intravitreal injections: Treatment.Route
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 carotid insufficiency, coagulopathy and poorly controlled diabetes mellitus: Effect; intravitreal injections of bevacizumab: Treatment; bevacizumab: Treatment.Drug; intravitreal injections: Treatment.Route